WO2016100516A1 - Oral care composition comprising cannabinoids - Google Patents
Oral care composition comprising cannabinoids Download PDFInfo
- Publication number
- WO2016100516A1 WO2016100516A1 PCT/US2015/066099 US2015066099W WO2016100516A1 WO 2016100516 A1 WO2016100516 A1 WO 2016100516A1 US 2015066099 W US2015066099 W US 2015066099W WO 2016100516 A1 WO2016100516 A1 WO 2016100516A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cannabinoid
- sodium
- group
- cannabinoids
- toothpaste
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
Definitions
- the present invention relates to cannabinoid oral care compositions, specifically dentifrice in paste and powder form and mouthwash, methods to prepare the dentifrice and mouthwash, and methods to administer the dentifrice or mouthwash to a human subject.
- the present invention also relates to methods to treat oral infectious conditions using these oral care compositions.
- Dentifrices are used with toothbrushes to clean and polish teeth. They come in powder, paste, liquid, or gel form, the most popular of which are known as toothpaste and tooth powder, both discussed below. People mainly use dentifrices to prevent dental plaque and remove food debris after eating.
- Toothpastes are made up of abrasives, binders, surfactants, and humectants; dentists normally recommend toothpaste that also contains fluoride. While the main purpose of toothpaste is to maintain oral hygiene by cleaning teeth and removing food particles, toothpastes can also be manufactured to help freshen breath and whiten teeth. Early toothpaste began with the Greeks followed by the Romans, which was then imported into 9th Century Persia. Modern toothpaste began to appear in the late 19th Century, and fluoride was first added into toothpaste in the 1890's.
- Toothpaste is manufactured typically by first preparing the liquid base, which is made up of water, sorbitol/glycerin, and other liquid ingredients.
- Rheology modifiers may be pre- mixed with a non-aqueous liquid ingredient such as glycerin or flavoring oil, or dry blended with other powder ingredients to aid dispersion.
- the active ingredients, sweeteners, and preservatives are added and dispersed.
- the abrasive is then added, followed by flavoring and coloring agents. Finally, a foaming agent is added under slow speed agitation to avoid foaming.
- Tooth powders are manufactured similarly to toothpastes, but without the liquid ingredients, giving only powder as the final product. Other ingredients such as flavoring oils can be added as preferred by the manufacturer.
- Dental caries are common infectious diseases affecting billions of people in the world. Dental hygiene, including frequent teeth brushing and use of fluoride-containing dentifrice and/or mouthwash, improves dental health. Fluoride compounds are commonly added into dentifrices for anti-bacterial purposes. Fluoride compounds also act to reinforce the calcium structure of teeth, by inhibiting the initiation of dental caries. However, an excessive dosage of fluoride compounds can lead to white spots on teeth.
- Bacteria present in the oral cavity are mostly Streptococcus mutatis, Escherichia coli, and Candida albicans. S. mutans infects the throat, causing "strep throat," E. coli causes digestive tract infections, while C. albicans promotes dental caries. For these reasons, antibacterial toothpaste is manufactured. Common anti-bacterial toothpaste additives include triclosan and chlorhexidine. There have been some concerns that triclosan may cause hormone imbalance in animals. Most importantly, anti-bacterial additives are believed to cause anti-bacterial resistant bacteria to spread.
- the cannabis plant has many naturally occurring substances that are of great interest in the fields of science and medicine.
- Isolated compounds from the cannabis plant include A 9 -tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabidivarin (CBDV), among other compounds. While THC has psychoactive effects, CBD, CBC, CBG, and CBDV do not.
- Isolated compounds from the cannabis plant are called cannabinoids. There are a total of eighty-five (85) cannabinoids that have been isolated from the cannabis plant. Many researchers have confirmed the medicinal value of cannabinoids. Cannabinoids have been investigated for possible treatment of seizures, nausea, vomiting, lack of appetite, pain, arthritis, inflammation, and other conditions.
- THC The IUPAC nomenclature of THC is (-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl- 6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-l-ol.
- CBD's IUPAC nomenclature is 2-((lS,6S)-3- methyl-6-(prop-l-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-l,3-diol).
- CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol. These are among the most prominent compounds in the family of compounds extracted from the cannabis plant referred to as cannabinoids.
- Cannabinoids may be isolated by extraction or cold pressing of cannabis plants. Plants in the cannabis genus include Cannabis sativa, Cannabis ruderalis, and Cannabis indica. These plants are the natural sources of cannabinoids. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are still currently practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in.
- Nabilone (racemic(6aR,10aR)-l-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)- 7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one), a synthetic cannabinoid, is believed to have fewer undesired side effects than THC. Nabilone mimics the chemical compound structure of THC. THC also exists in synthetic form under the name Dronabinol ((-)-(6aR,10aR)-6,6,9- trimythel-3-pentyl-6a,7,8, 10a-tetrahydro-6H-benzo[c]chromen- l-ol)). These synthetic cannabinoids are investigated for medicinal purposes. The U.S. Food and Drug Administration approved nabilone for treatment of chemotherapy-induced nausea and vomiting. In the United States, nabilone is marketed under the name Cesamet ® .
- Cannabidiol from hemp is marketed in the United States.
- Various products containing cannabidiol have been marketed in recent years.
- Cannabidiol may be consumed by ingestion, by inhalation, or by transdermal delivery.
- CBD, CBG, and THC have anti-bacterial properties, with fast acting mechanisms. These cannabinoids are anti-bacterial, with a minimum inhibitory concentration at between 0.5 - 2 ⁇ g/ml for various Staphylococcus aureus strains.
- the present invention is directed at an oral care composition, specifically a dentifrice and a mouthwash solution containing at least one cannabinoid having anti-bacterial properties.
- the at least one cannabinoid is present in an amount adequate to give anti-bacterial properties to the dentifrice; while at the same time is unlikely to cause an overdose of anti-bacterial compounds in dentifrice.
- the present invention also relates to methods to treat oral infectious diseases using the dentifrice and/or mouthwash solution comprising cannabinoids.
- CBDV Cannabidivarin
- CBD Cannabidiol
- CBG Cannabigerol
- THC Tetrahydrocannabinols
- cannabinoid used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor and other cannabinoid mimetics, including, but not limited to, certain tetrahydropyran analogs ⁇ -tetrahydrocannabinol, A 8 -tetrahydrocannabinol, 6,6,9-trimythel-3-pentyl-6H-dibenzo[b,d]pyran-l-ol,3-(l,l- dimethylheptyl)-6,6a7,8,10,10a-hexahydro-l-lhydroxy-6,6-dimythel-9H-dibezo[b,d]pyran-9- ol,(-)-(3S,4S)-7-hydroxy-delta-6-tetrahydrocannabinol-l,l-dimethylheptyl, (+)-(3S,4S)-7-
- cannabidiol refers to cannabidiol and cannabidiol derivatives.
- cannabidiol is obtained from industrial hemp extract with a trace amount of THC or from cannabis extract using high-CBD cannabis cultivars.
- annabigerol refers to cannabigerol and cannabigerol derivatives. As used in this application, cannabigerol is derived from industrial hemp extract with a trace amount of THC or from cannabis extract.
- Toothpaste is manufactured by producing a prewetted binder with a humectant, and then dispersing the mixture into the liquid phase of the formulation. The entire mixture is mixed in a mixer to form a uniform paste. Alternatively, the binder is premixed with solid abrasives and then introduced into a mixing liquid phase of the formulation.
- Cannabinoids used in this embodiment may be in liquid form, as a natural constituent of hemp oil or cannabis oil. Hemp oil or cannabis oil is harvested by cold pressing the seeds and the plants of the Cannabis sativa species. The resulting oil is extracted using C0 2 extraction or solvent extraction process, and may be further concentrated by distillation. Choice of cultivars may give different cannabinoid concentrations, but preferably, the targeted cannabinoids are cannabidiol (CBD) and cannabigerol (CBG). Other cannabinoids such as THC and cannabichromene (CBC) may also be present in hemp oil or cannabis oil. Further isolation of these cannabinoids may result in solid, purified cannabinoids.
- CBD cannabidiol
- CBG cannabigerol
- Other cannabinoids such as THC and cannabichromene (CBC) may also be present in hemp oil or cannabis oil. Further isolation of these cannabinoids may result in solid, purified cannabinoids.
- toothpaste is manufactured with one or more cannabinoids incorporated for anti-bacterial effects.
- the one or more cannabinoids are naturally derived or artificially derived.
- hemp oil or cannabis oil may contain up to 85% impurities, including fatty acids and other plant impurities.
- the extracted oil is then distilled to increase the cannabinoid concentration.
- Impurities in hemp oil and cannabis oil may be fatty acids such as linoleic acid and a-linoleic acid, which are natural components of hemp oil or cannabis oil, ⁇ -caryophyllene, myrcene, and ⁇ -sitosterol.
- cannabinoids provided as hemp oil or cannabis oil may contain impurities in an amount of less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 55%, less than 50%, less than 45%, less than 40%, or less than 35% by weight.
- cannabinoids may have anti-bacterial properties, including ⁇ 9 - tetrahydrocannabinols
- non-psychoactive cannabinoids are preferred in this invention such that the embodiments may be used by all consumers. It is to be appreciated that psychoactive cannabinoids are included within the scope of the invention in certain embodiments, in cases where the psychoactive effect is unimportant.
- the viscosity of the oil is high, usually in a paste-like matrix.
- the cannabinoid-containing oil is combined with a binder and a humectant before introduction into the liquid phase.
- the cannabinoid oil is premixed with the binder and a solid abrasive before introduction into the liquid phase for mixing.
- Hemp oil or cannabis oil with naturally occurring cannabinoids may have more than one cannabinoids.
- hemp oil or cannabis oil is used to incorporate cannabinoid into toothpaste, the total cannabinoid content of the cannabis oil or hemp oil after addition into the toothpaste is at 0.1% to 0.5% by weight.
- Solid and isolated cannabinoids may also be used.
- Solid cannabinoids may be combined with the binder and a humectant before introduction into the liquid phase.
- Solid cannabinoid(s) may also be mixed with the binder and a solid abrasive prior to introduction into the liquid phase.
- Solid cannabinoids are present in the toothpaste at 0.1% to 0.5% by weight.
- Abrasive agents used in toothpaste manufacturing according to this embodiment may be hydrated alumina, silica, water-insoluble sodium metaphosphate, tricalcium phosphate, calcium phosphate dihydrate, anhydrous dicalcium phosphate, calcium pyrophosphate, calcium carbonate, sodium bicarbonate, or aluminum silicate.
- Commercially available abrasive agents such as Zeodent 113, Zeodent 115, or Zeodent 116 (silica abrasive agents) may be used.
- a combination of abrasive agents may also be used.
- Abrasive agents may be present in this embodiment at between 5% and 15% by weight.
- a thickener, such as Zeodent 163, may be used together with other cleansing silica materials to thicken the toothpaste to a desirable viscosity. The thickener is present in the toothpaste at between 2% and 15% by weight.
- Binders used in toothpaste manufacturing may be chosen from plant gum such as guar gum or xanthan gum, sodium alginate, karaya gum, bentonite, carrageenan, blanose cellulose gum, methylcellulose, and PEG- 1500.
- the amount of binder present in this toothpaste may be at 0.2% to 2.5% by weight.
- Humectants may retain water in the toothpaste matrix and keep toothpaste from drying out. Sorbitol, glycerin, and propylene glycol may be used as humectants. Glycerin and sorbitol may also give the sweet taste to the toothpaste as a whole.
- Sorbitol may be present in this toothpaste at a 70% aqueous solution.
- sorbitol solution may be present at between 25% and 75% by weight of the toothpaste.
- glycerin may be present at between 25% and 75% by weight of the toothpaste. Glycerin has a sweetness of about 60% that of table sugar and additional sweeteners may be added to improve the toothpaste's taste.
- the toothpaste according to this embodiment may have one or more fluoride compounds to prevent dental caries.
- Suitable fluoride compounds may be sodium monofluorophosphate and sodium fluoride.
- the fluoride compound may be present in the toothpaste at 0.1% to 1% by weight.
- the one or more cannabinoids may be present at 0.1% to 0.5% by weight, more specifically at 0.2% to 0.4% by weight.
- at least one cannabinoid may be present to comprise between 0.1% and 0.5% by weight of the toothpaste.
- adding one isolated purified cannabinoid preferably chosen from the group comprising of CBD, CBG, THC and CBC, is recommended.
- the amount of the artificial cannabinoid may be at 0.1% to 0.5% by weight of the toothpaste.
- Lactoferrin may be added into the toothpaste in this embodiment at 0.1% to 0.5% by weight. Lactoferrin attacks biofilm bacteria and works as a wound dressing agent to speed up wound healing. In the oral cavity, biofilm bacteria are a major concern.
- Anti-inflammation agents may be added into the toothpaste at 0.2% to 0.6% by weight. Magnesium sulfate has anti-inflammation properties as well as coagulant properties to stop bleeding, and may be added into the toothpaste according to this embodiment.
- Foaming agents or surfactants may be added to toothpaste to create the foam appearance during brushing.
- Surfactants such as sodium lauryl sulfate, sodium lauryl sulfoacetate, dioctyl sodium sulfosuccinate, sulfolaurate, sodium lauryl sarcosinate, sodium stearyl fumarate, and sodium stearyl lactate may be added into the toothpaste.
- Commercially available foaming agents such as cocamidopropyl betaine (available as Tego Betain ZF, sold by Evonik Industries AG Personal Care) may also be used as surfactants.
- compositions of the toothpaste may be used in sufficient amounts, including water, other preservatives, sweeteners, and flavoring oils.
- Flavoring oils as used this embodiment may be wintergreen, peppermint, spearmint, cinnamon, orange, watermelon, citrus, peach, apricot, anise, vanilla, clove, green tea, caraway, eucalyptus, sage, thyme, bourbon, rye, or any suitable flavors. Multiple flavors may be added.
- Coloring agents to give the toothpaste a desirable color may be added.
- Popular colors are white, blue, red, orange, and green. Coloring agents may be present in the toothpaste at 1% to 3% by weight.
- Preservatives suitable for food products may be added into the toothpaste. Suitable preservatives include citric acid, trisodium citrate, alcohols, benzoates, and dichlorinated phenols. Citric acid and citrates are preferred preservatives. Preservatives may be present at 0.05% to 2% by weight.
- Abrasive agents, humectants, binders, and cannabinoids may be combined and mixed in a container, forming the first phase.
- the liquid phase, or the second phase including water, fluoride compounds, preservatives, coloring agents, sweeteners, and flavoring oils, may be combined and mixed.
- the first phase may be mixed into the second phase and stirred well with a propeller. Temperature control to keep the mixture from drying out is desirable.
- tooth powder with cannabinoids added for anti-bacterial purposes is disclosed. Tooth powder may be used in the same manner as toothpaste. Tooth powder contains similar ingredients with toothpaste, but without water and binders. [0055] In this embodiment, solid isolated cannabinoid(s) may be used in the manufacturing of dentifrices. Isolated cannabinoids may be in fine powder form and may be effective when combined into dentifrice powder. Grain size may be modified and adjusted to avoid sieving effects and separation of grains within the dentifrice powder.
- the tooth powder may contain one or more abrasive agents.
- the one or more abrasive agent may be chosen from a group comprising of baking soda, chalk, clay, activated carbon, or pumice powder.
- One or more cannabinoids in powder form may be added into the tooth powder in this embodiment.
- One or more cannabinoids may be present in the tooth powder at 0.05% to 0.3% by weight.
- the cannabinoids added to tooth powder may be derived from natural sources. Hemp oil or cannabis oil with naturally occurring cannabinoids may be freeze dried, or granulated and purified, and the resulting powder, which is high in cannabinoids, may be added into tooth powder at 0.05% to 0.5% by weight.
- Synthetic cannabinoids may also be added into tooth powder. Synthetic cannabinoids are typically in powder form and mix well into tooth powder. The proportion of synthetic cannabinoids added may be at 0.05% to 0.5% by weight.
- the tooth powder may further comprise a sweetener for taste improvement purposes.
- Xylitol is the preferred sweetener as it is available in powder form and does not cause dental caries. Saccharin may also be used, but due to its strong sweet taste, the proportion added should be low.
- the proportion of the sweetener is according to taste, but preferably at 0.5% to 10% by weight of the tooth powder.
- the tooth powder may further comprise other additives for flavor, such as sage, spearmint, peppermint essential oil, wintergreen essential oil, lemon oil, orange oil, anise oil, or cinnamon oil. Flavors are available in essential oil and may be combined into the tooth powder by mixing.
- Components of the tooth powder according to this embodiment are mixed by a solid mixer for even distribution.
- the toothpaste or tooth powder according to these embodiments is used by placing a sufficient quantity on a toothbrush.
- a human subject applies agitating force to his or her teeth using the toothbrush with the toothpaste or tooth powder.
- the human subject rinses his or her mouth with drinking water.
- a mouthwash solution comprising cannabinoids.
- This cannabinoid mouthwash solution may have anti-bacterial properties and inhibits growth of harmful bacteria in the oral cavity.
- one or more cannabinoids may be added as isolated cannabinoids, either naturally or artificially derived. Isolated cannabinoids are in powder form and requires relatively smaller emulsifying capacity when mixed into a water/ethanol solution. Cannabinoids provided as hemp oil or cannabis oil may be incorporated, but preferably with higher emulsification load. The resulting mouthwash solution using hemp oil or cannabis oil may separate.
- Cannabinoids as used in this embodiment are THC, CBD, and CBG, preferably CBD and CBG. A combination of different cannabinoids may be used in this embodiment. Cannabinoids are present in this embodiment at 0.5% to 4% by weight of the mouthwash solution.
- hemp oil or cannabis oil with high cannabinoid concentration the total cannabinoid content added may be present at 0.5% to 4% by weight of the mouthwash.
- a combination of cannabinoids may be present.
- the mouthwash solution may include surfactants.
- Suitable nonionic surfactants may be poly-ethoxylated sorbitol esters, polycondensates of ethylene oxide and propylene oxide, poly-ethoxylated hydrogenated castor oil (available as Eumulgin HRE40, sold by BASF).
- Suitable anionic surfactants are sodium dodecyl sulfate (sodium laurylsulfate), sodium laureth sulfate, sodium lauroyl sarcosinate, and potassium lauryl sulfate.
- Suitable amphoteric surfactants include, for example, long chain imidazoline and long chain alkyl betaines.
- Suitable cationic surfactants include D,L-2-pyrrolidone-5-carboxylic acid salt of ethyl-N-cocoyl-L-alginate and cocamidopropyl PG dimonium chloride phosphate. Surfactants may be present in this embodiment at 0.5% to 10% (w/w), more preferably at 0.5% to 5% (w/w).
- the mouthwash solution may further include thickeners.
- Suitable thickeners may be methylcellulose, hydroxyalkylcellulose ethers, alkylcellulose ethers, hydroxypropyl methylcellulose, gum tragancanth, sodium carboxymethylcellulose, blanose cellulose gum (available as Blanose 7LF, sold by Ashland), polyvinyl pyrrolidone (available as Plasdone C-30, sold by Ashland), and carrageenan.
- Thickeners also act as emulsifiers to promote mixing in the suspension.
- the thickening agent may be present in the mouthwash solution at 0.5% to 5% (w/w).
- the mouthwash solution preferably further comprises a humectant.
- Humectants retain water and prevent the solution from drying out.
- Suitable humectants may be chosen from a group comprising of glycerine, sorbitol, propylene glycol, and polyethylene glycol. A combination of more than one humectants may also be used. Humectants may be present in the mouthwash solution at 2% to 10% (w/w).
- the mouthwash may further include cavity prevention and/or re-mineralization agents.
- Suitable cavity prevention or remineralization agents may be sodium monofluorophosphate and sodium fluoride.
- the cavity prevention agent may be present in the mouthwash solution at 0.01% to 0.5% (w/w).
- the mouthwash according to this embodiment may further comprise an additional anti-bacterial agent such as lactoferrin. Lactoferrin attacks biofilm bacteria and acts as a wound- dressing agent to promote healing.
- lactoferrin attacks biofilm bacteria and acts as a wound- dressing agent to promote healing.
- the mouthwash according to this embodiment may further comprise at least one flavor.
- Flavors as used this embodiment may be wintergreen, peppermint, spearmint, cinnamon, orange, watermelon, citrus, peach, apricot, anise, vanilla, clove, green tea, caraway, eucalyptus, sage thyme, bourbon, rye, or any suitable flavors. Multiple flavors may be added.
- Coloring agents to give the mouthwash a desirable color may be added.
- Popular colors may be white, blue, orange, gold, and green. Coloring agents may be present in the mouthwash at 1% to 3% by weight.
- Preservatives suitable for food products may be added into the mouthwash according to this embodiment. Suitable preservatives include citric acid, trisodium citrate, alcohols, sodium paraben, benzoates, and dichlorinated phenols. Preservatives may be present at 0.05% to 2% (w/w).
- the mouthwash solution may have an aqueous base comprising water and ethanol. Ethanol increases solubility of powder cannabinoids. Ethanol may be present in this mouthwash at 5% to 20% (w/w).
- the mouthwash solution may be used by a mammal, preferably a human being, by placing an appropriate amount of the mouthwash in the human subject's mouth, the human subject holds the mouthwash in the oral cavity for at least thirty (30) seconds, and the human subject spits the mouthwash out.
- Various oral infectious diseases may be treated with cannabinoid oral care solutions due to their antibacterial, pain relieving, wound dressing, and anti-inflammation properties.
- Conditions treated by these cannabinoid oral care compositions may include periimplantitis, periodontitis, oral mucositis (especially oral mucositis caused by chemotherapy in cancer treatment), and dental pain.
- Cannabinoid dentifrice including cannabinoid toothpaste and cannabinoid tooth powder, may be used in teeth brushing at a therapeutically effective amount to treat periimplantitis, periodontitis, oral mucositis, and dental pain.
- Cannabinoid mouthwash may be used in conjunction with, or separately from, cannabinoid dentifrice.
- a therapeutically effective amount of cannabinoid mouthwash may be held in the oral cavity of a human subject for at least thirty seconds before spitting out for treatment of periimplantitis, periodontitis, oral mucositis, and dental pain.
- Other ingredients are purified water, FD&C Blue No.1 (0.2% solution) for coloring, methyl salicilate (wintergreen flavor), Flavor RV35640 (peppermint flavor), sodium methylparaben (preservative), citric acid (preservative), saccharine (flavor), xylitol (cavity prevention), magnesium sulfate7.aq (anti-inflammation agent), sodium fluoride (remineralized agent), hemp oil with 3% w/w CBD and 17% w/w CBG (anti-bacterial agent, wound dressing agent), lactoferrin (anti-bacterial agent, wound dressing agent).
- Flavor RV35640 Peppermint 1.5000 45.0000
- Stage 1 450 grams of water are placed in the main mixer.
- Stage 2 15 grams of Blanose CMC 12M31XP, 240 grams of Zeodent 113 and Zeodent 163 each, and 60 grams of hemp oil (CBD/CBG 3%/17% w/w) ) are dry mixed in a different vessel, then added into the main mixer. The main mixer mixes for 10 minutes and produces a cream-like paste.
- Stage 3 In a different vessel, mix 1200 grams of the glycerin solution, saccharine, sodium fluoride, sodium methylparaben, xylitol, citric acid, trisodium citrate.2aq Ph Eur, magnesium sulfate. 7aq, PEG 1500, and lactoferrin. The vessel is heated to increase dissolution. This mixture is added into the main mixer and mixed for 15 minutes.
- Stage 4 A mixture of Tego Betain ZF and the rest of the glycerin solution is added into the main mixer and mixed for 15 minutes.
- Stage 5 Methyl salicilate and peppermint flavor are added into the main mixer and mixed for another 10 minutes. The toothpaste is then packed into tubes or pump containers.
- Example 2 Methyl salicilate and peppermint flavor are added into the main mixer and mixed for another 10 minutes. The toothpaste is then packed into tubes or pump containers.
- CBD/CBG (3%/17%) 0.060 0.600
- Flavor RV35641 Peppermint 0.300 ! 3.000 I
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
This application discloses oral care compositions comprising cannabinoids, preferably cannabidiol and/or cannabigerol. The oral care composition disclosed in this application may be a tooth paste, a tooth powder, or a mouthwash solution. The oral care composition may be used to treat oral infectious disease, including periimplantitis, periodontitis, oral mucositis, and dental pain.
Description
ORAL CARE COMPOSITION COMPRISING CANNABINOIDS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to United States Provisional Application No.62/092,609, filed December 16, 2014, the content of which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention
[0002] The present invention relates to cannabinoid oral care compositions, specifically dentifrice in paste and powder form and mouthwash, methods to prepare the dentifrice and mouthwash, and methods to administer the dentifrice or mouthwash to a human subject. The present invention also relates to methods to treat oral infectious conditions using these oral care compositions.
Description of the Related Technology
[0003] Dentifrices are used with toothbrushes to clean and polish teeth. They come in powder, paste, liquid, or gel form, the most popular of which are known as toothpaste and tooth powder, both discussed below. People mainly use dentifrices to prevent dental plaque and remove food debris after eating.
[0004] Toothpastes are made up of abrasives, binders, surfactants, and humectants; dentists normally recommend toothpaste that also contains fluoride. While the main purpose of toothpaste is to maintain oral hygiene by cleaning teeth and removing food particles, toothpastes can also be manufactured to help freshen breath and whiten teeth. Early toothpaste began with the Greeks followed by the Romans, which was then imported into 9th Century Persia. Modern toothpaste began to appear in the late 19th Century, and fluoride was first added into toothpaste in the 1890's.
[0005] Toothpaste is manufactured typically by first preparing the liquid base, which is made up of water, sorbitol/glycerin, and other liquid ingredients. Rheology modifiers may be pre- mixed with a non-aqueous liquid ingredient such as glycerin or flavoring oil, or dry blended with other powder ingredients to aid dispersion. The active ingredients, sweeteners, and preservatives
are added and dispersed. The abrasive is then added, followed by flavoring and coloring agents. Finally, a foaming agent is added under slow speed agitation to avoid foaming.
[0006] Tooth powders are manufactured similarly to toothpastes, but without the liquid ingredients, giving only powder as the final product. Other ingredients such as flavoring oils can be added as preferred by the manufacturer.
[0007] Dental caries are common infectious diseases affecting billions of people in the world. Dental hygiene, including frequent teeth brushing and use of fluoride-containing dentifrice and/or mouthwash, improves dental health. Fluoride compounds are commonly added into dentifrices for anti-bacterial purposes. Fluoride compounds also act to reinforce the calcium structure of teeth, by inhibiting the initiation of dental caries. However, an excessive dosage of fluoride compounds can lead to white spots on teeth.
[0008] Bacteria present in the oral cavity are mostly Streptococcus mutatis, Escherichia coli, and Candida albicans. S. mutans infects the throat, causing "strep throat," E. coli causes digestive tract infections, while C. albicans promotes dental caries. For these reasons, antibacterial toothpaste is manufactured. Common anti-bacterial toothpaste additives include triclosan and chlorhexidine. There have been some concerns that triclosan may cause hormone imbalance in animals. Most importantly, anti-bacterial additives are believed to cause anti-bacterial resistant bacteria to spread.
[0009] The cannabis plant has many naturally occurring substances that are of great interest in the fields of science and medicine. Isolated compounds from the cannabis plant include A9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabidivarin (CBDV), among other compounds. While THC has psychoactive effects, CBD, CBC, CBG, and CBDV do not. Isolated compounds from the cannabis plant are called cannabinoids. There are a total of eighty-five (85) cannabinoids that have been isolated from the cannabis plant. Many researchers have confirmed the medicinal value of cannabinoids. Cannabinoids have been investigated for possible treatment of seizures, nausea, vomiting, lack of appetite, pain, arthritis, inflammation, and other conditions.
[0010] The IUPAC nomenclature of THC is (-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl- 6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-l-ol. CBD's IUPAC nomenclature is 2-((lS,6S)-3- methyl-6-(prop-l-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-l,3-diol). CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol. These are among the
most prominent compounds in the family of compounds extracted from the cannabis plant referred to as cannabinoids.
[0011] Cannabinoids may be isolated by extraction or cold pressing of cannabis plants. Plants in the cannabis genus include Cannabis sativa, Cannabis ruderalis, and Cannabis indica. These plants are the natural sources of cannabinoids. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are still currently practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in.
[0012] Nabilone (racemic(6aR,10aR)-l-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)- 7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one), a synthetic cannabinoid, is believed to have fewer undesired side effects than THC. Nabilone mimics the chemical compound structure of THC. THC also exists in synthetic form under the name Dronabinol ((-)-(6aR,10aR)-6,6,9- trimythel-3-pentyl-6a,7,8, 10a-tetrahydro-6H-benzo[c]chromen- l-ol)). These synthetic cannabinoids are investigated for medicinal purposes. The U.S. Food and Drug Administration approved nabilone for treatment of chemotherapy-induced nausea and vomiting. In the United States, nabilone is marketed under the name Cesamet®.
[0013] Cannabidiol from hemp is marketed in the United States. Various products containing cannabidiol have been marketed in recent years. Cannabidiol may be consumed by ingestion, by inhalation, or by transdermal delivery.
[0014] CBD, CBG, and THC have anti-bacterial properties, with fast acting mechanisms. These cannabinoids are anti-bacterial, with a minimum inhibitory concentration at between 0.5 - 2 μg/ml for various Staphylococcus aureus strains.
SUMMARY
[0015] The present invention is directed at an oral care composition, specifically a dentifrice and a mouthwash solution containing at least one cannabinoid having anti-bacterial properties. The at least one cannabinoid is present in an amount adequate to give anti-bacterial properties to the dentifrice; while at the same time is unlikely to cause an overdose of anti-bacterial compounds in dentifrice. The present invention also relates to methods to treat oral infectious diseases using the dentifrice and/or mouthwash solution comprising cannabinoids.
ABBREVIATIONS
[0016] CBC: Cannabichromen
[0017] CBDV: Cannabidivarin
[0018] CBD: Cannabidiol
[0019] CBG: Cannabigerol
[0020] IUPAC: International Union of Pure and Applied Chemistry
[0021] THC: Tetrahydrocannabinols
[0022] W/w: weight/weight
DETAILED DESCRIPTION OF CERTAIN INVENTIVE EMBODIMENTS
[0023] This present invention is capable of being embodied in various forms. The description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the attached claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience only and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
[0024] As used herein, the verb "to comprise" in this description, claims, and other conjugations are used in its non-limiting sense to mean those items following the word are included, but items not specifically mentioned are not excluded.
[0025] Reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one." Additionally, the words "a" and "an" when used in the present document in concert with the words "comprising" or "containing" denote "one or more."
[0026] The word "cannabinoid" used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor and other cannabinoid mimetics, including, but not limited to, certain tetrahydropyran analogs ^-tetrahydrocannabinol, A8-tetrahydrocannabinol, 6,6,9-trimythel-3-pentyl-6H-dibenzo[b,d]pyran-l-ol,3-(l,l- dimethylheptyl)-6,6a7,8,10,10a-hexahydro-l-lhydroxy-6,6-dimythel-9H-dibezo[b,d]pyran-9- ol,(-)-(3S,4S)-7-hydroxy-delta-6-tetrahydrocannabinol-l,l-dimethylheptyl, (+)-(3S,4S)-7-
hydroxy-A-6-tetrahydrocannabinol, and A8-tetrahydrocannabinol-l l-oic acid); certain piperidine analogs (e.g., (-)-(6S,6aR,9R,10aR)-5,6,6a,7,8,9,10,10a-octahydro-6-methyl-l-3-[(R)-l-methyl- 4-phenylbutoxy]-l,9-phenanthridinediol 1 -acetate)); certain aminoalkylindole analogs (e.g., (R)- (+)-[2,3-dihydro-5-methyl-3-(4-morpholinylm-ethyl)-pyrrolo[ 1,2,3, -de]- l,4-benzoxazin-6-yl]-l- naphthelenyl-methanone); certain open pyran-ring analogs (e.g., 2-[3-methyl-6-(l-methylethenyl- 2-cyclohexen-l-yl]-5-pentyl-l, 3-benzendi-ol, and 4-(l,l-dimethylheptyl)-2,3'-dihydroxy-6'-a- (3-hydroxypropyl)- ,-2',3',4',5',6'-hexahydrobiphenyl), their salts, solvates, metabolites, and metabolic precursors.
[0027] The word "cannabidiol" refers to cannabidiol and cannabidiol derivatives. As used in this application, cannabidiol is obtained from industrial hemp extract with a trace amount of THC or from cannabis extract using high-CBD cannabis cultivars.
[0028] The word "cannabigerol" refers to cannabigerol and cannabigerol derivatives. As used in this application, cannabigerol is derived from industrial hemp extract with a trace amount of THC or from cannabis extract.
[0029] Toothpaste is manufactured by producing a prewetted binder with a humectant, and then dispersing the mixture into the liquid phase of the formulation. The entire mixture is mixed in a mixer to form a uniform paste. Alternatively, the binder is premixed with solid abrasives and then introduced into a mixing liquid phase of the formulation.
[0030] Cannabinoids used in this embodiment may be in liquid form, as a natural constituent of hemp oil or cannabis oil. Hemp oil or cannabis oil is harvested by cold pressing the seeds and the plants of the Cannabis sativa species. The resulting oil is extracted using C02 extraction or solvent extraction process, and may be further concentrated by distillation. Choice of cultivars may give different cannabinoid concentrations, but preferably, the targeted cannabinoids are cannabidiol (CBD) and cannabigerol (CBG). Other cannabinoids such as THC and cannabichromene (CBC) may also be present in hemp oil or cannabis oil. Further isolation of these cannabinoids may result in solid, purified cannabinoids.
[0031] In a preferred embodiment, toothpaste is manufactured with one or more cannabinoids incorporated for anti-bacterial effects. In this embodiment, the one or more cannabinoids are naturally derived or artificially derived.
[0032] When cannabinoids are provided as hemp oil or cannabis oil, the hemp oil or cannabis oil may contain up to 85% impurities, including fatty acids and other plant impurities.
The extracted oil is then distilled to increase the cannabinoid concentration. Impurities in hemp oil and cannabis oil may be fatty acids such as linoleic acid and a-linoleic acid, which are natural components of hemp oil or cannabis oil, β-caryophyllene, myrcene, and β-sitosterol.
[0033] In this embodiment, cannabinoids provided as hemp oil or cannabis oil may contain impurities in an amount of less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 55%, less than 50%, less than 45%, less than 40%, or less than 35% by weight.
[0034] While many cannabinoids may have anti-bacterial properties, including Δ9- tetrahydrocannabinols, non-psychoactive cannabinoids are preferred in this invention such that the embodiments may be used by all consumers. It is to be appreciated that psychoactive cannabinoids are included within the scope of the invention in certain embodiments, in cases where the psychoactive effect is unimportant.
[0035] When the oily form of cannabinoids is used, the viscosity of the oil is high, usually in a paste-like matrix. The cannabinoid-containing oil is combined with a binder and a humectant before introduction into the liquid phase. Alternatively, the cannabinoid oil is premixed with the binder and a solid abrasive before introduction into the liquid phase for mixing.
[0036] Hemp oil or cannabis oil with naturally occurring cannabinoids may have more than one cannabinoids. When hemp oil or cannabis oil is used to incorporate cannabinoid into toothpaste, the total cannabinoid content of the cannabis oil or hemp oil after addition into the toothpaste is at 0.1% to 0.5% by weight.
[0037] Solid and isolated cannabinoids may also be used. Solid cannabinoids may be combined with the binder and a humectant before introduction into the liquid phase. Solid cannabinoid(s) may also be mixed with the binder and a solid abrasive prior to introduction into the liquid phase. Solid cannabinoids are present in the toothpaste at 0.1% to 0.5% by weight.
[0038] Abrasive agents used in toothpaste manufacturing according to this embodiment may be hydrated alumina, silica, water-insoluble sodium metaphosphate, tricalcium phosphate, calcium phosphate dihydrate, anhydrous dicalcium phosphate, calcium pyrophosphate, calcium carbonate, sodium bicarbonate, or aluminum silicate. Commercially available abrasive agents such as Zeodent 113, Zeodent 115, or Zeodent 116 (silica abrasive agents) may be used. A combination of abrasive agents may also be used. Abrasive agents may be present in this embodiment at between 5% and 15% by weight.
[0039] A thickener, such as Zeodent 163, may be used together with other cleansing silica materials to thicken the toothpaste to a desirable viscosity. The thickener is present in the toothpaste at between 2% and 15% by weight.
[0040] Binders used in toothpaste manufacturing may be chosen from plant gum such as guar gum or xanthan gum, sodium alginate, karaya gum, bentonite, carrageenan, blanose cellulose gum, methylcellulose, and PEG- 1500. The amount of binder present in this toothpaste may be at 0.2% to 2.5% by weight.
[0041] Humectants may retain water in the toothpaste matrix and keep toothpaste from drying out. Sorbitol, glycerin, and propylene glycol may be used as humectants. Glycerin and sorbitol may also give the sweet taste to the toothpaste as a whole.
[0042] Sorbitol may be present in this toothpaste at a 70% aqueous solution. In a toothpaste composition, sorbitol solution may be present at between 25% and 75% by weight of the toothpaste.
[0043] Where glycerin is used as a humectant, glycerin may be present at between 25% and 75% by weight of the toothpaste. Glycerin has a sweetness of about 60% that of table sugar and additional sweeteners may be added to improve the toothpaste's taste.
[0044] The toothpaste according to this embodiment may have one or more fluoride compounds to prevent dental caries. Suitable fluoride compounds may be sodium monofluorophosphate and sodium fluoride. The fluoride compound may be present in the toothpaste at 0.1% to 1% by weight.
[0045] In the toothpaste, the one or more cannabinoids may be present at 0.1% to 0.5% by weight, more specifically at 0.2% to 0.4% by weight. For naturally derived cannabinoids, wherein the hemp oil or cannabis oil has multiple cannabinoids, at least one cannabinoid may be present to comprise between 0.1% and 0.5% by weight of the toothpaste. For artificially derived cannabinoids, adding one isolated purified cannabinoid, preferably chosen from the group comprising of CBD, CBG, THC and CBC, is recommended. The amount of the artificial cannabinoid may be at 0.1% to 0.5% by weight of the toothpaste.
[0046] Lactoferrin may be added into the toothpaste in this embodiment at 0.1% to 0.5% by weight. Lactoferrin attacks biofilm bacteria and works as a wound dressing agent to speed up wound healing. In the oral cavity, biofilm bacteria are a major concern.
[0047] Anti-inflammation agents may be added into the toothpaste at 0.2% to 0.6% by weight. Magnesium sulfate has anti-inflammation properties as well as coagulant properties to stop bleeding, and may be added into the toothpaste according to this embodiment.
[0048] Foaming agents or surfactants may be added to toothpaste to create the foam appearance during brushing. Surfactants such as sodium lauryl sulfate, sodium lauryl sulfoacetate, dioctyl sodium sulfosuccinate, sulfolaurate, sodium lauryl sarcosinate, sodium stearyl fumarate, and sodium stearyl lactate may be added into the toothpaste. Commercially available foaming agents such as cocamidopropyl betaine (available as Tego Betain ZF, sold by Evonik Industries AG Personal Care) may also be used as surfactants.
[0049] Other components of the toothpaste may be used in sufficient amounts, including water, other preservatives, sweeteners, and flavoring oils.
[0050] Flavoring oils as used this embodiment may be wintergreen, peppermint, spearmint, cinnamon, orange, watermelon, citrus, peach, apricot, anise, vanilla, clove, green tea, caraway, eucalyptus, sage, thyme, bourbon, rye, or any suitable flavors. Multiple flavors may be added.
[0051] Coloring agents to give the toothpaste a desirable color may be added. Popular colors are white, blue, red, orange, and green. Coloring agents may be present in the toothpaste at 1% to 3% by weight.
[0052] Preservatives suitable for food products may be added into the toothpaste. Suitable preservatives include citric acid, trisodium citrate, alcohols, benzoates, and dichlorinated phenols. Citric acid and citrates are preferred preservatives. Preservatives may be present at 0.05% to 2% by weight.
[0053] Abrasive agents, humectants, binders, and cannabinoids may be combined and mixed in a container, forming the first phase. The liquid phase, or the second phase, including water, fluoride compounds, preservatives, coloring agents, sweeteners, and flavoring oils, may be combined and mixed. Then, the first phase may be mixed into the second phase and stirred well with a propeller. Temperature control to keep the mixture from drying out is desirable.
[0054] In another embodiment of this invention, tooth powder with cannabinoids added for anti-bacterial purposes is disclosed. Tooth powder may be used in the same manner as toothpaste. Tooth powder contains similar ingredients with toothpaste, but without water and binders.
[0055] In this embodiment, solid isolated cannabinoid(s) may be used in the manufacturing of dentifrices. Isolated cannabinoids may be in fine powder form and may be effective when combined into dentifrice powder. Grain size may be modified and adjusted to avoid sieving effects and separation of grains within the dentifrice powder.
[0056] In this embodiment, the tooth powder may contain one or more abrasive agents. The one or more abrasive agent may be chosen from a group comprising of baking soda, chalk, clay, activated carbon, or pumice powder.
[0057] One or more cannabinoids in powder form may be added into the tooth powder in this embodiment. One or more cannabinoids may be present in the tooth powder at 0.05% to 0.3% by weight.
[0058] Preferably, the cannabinoids added to tooth powder may be derived from natural sources. Hemp oil or cannabis oil with naturally occurring cannabinoids may be freeze dried, or granulated and purified, and the resulting powder, which is high in cannabinoids, may be added into tooth powder at 0.05% to 0.5% by weight.
[0059] Synthetic cannabinoids may also be added into tooth powder. Synthetic cannabinoids are typically in powder form and mix well into tooth powder. The proportion of synthetic cannabinoids added may be at 0.05% to 0.5% by weight.
[0060] The tooth powder may further comprise a sweetener for taste improvement purposes. Xylitol is the preferred sweetener as it is available in powder form and does not cause dental caries. Saccharin may also be used, but due to its strong sweet taste, the proportion added should be low. The proportion of the sweetener is according to taste, but preferably at 0.5% to 10% by weight of the tooth powder.
[0061] The tooth powder may further comprise other additives for flavor, such as sage, spearmint, peppermint essential oil, wintergreen essential oil, lemon oil, orange oil, anise oil, or cinnamon oil. Flavors are available in essential oil and may be combined into the tooth powder by mixing.
[0062] Components of the tooth powder according to this embodiment are mixed by a solid mixer for even distribution.
[0063] The toothpaste or tooth powder according to these embodiments is used by placing a sufficient quantity on a toothbrush. A human subject applies agitating force to his or her teeth
using the toothbrush with the toothpaste or tooth powder. The human subject rinses his or her mouth with drinking water.
[0064] In another embodiment of this invention, a mouthwash solution comprising cannabinoids is provided. This cannabinoid mouthwash solution may have anti-bacterial properties and inhibits growth of harmful bacteria in the oral cavity.
[0065] In this embodiment, one or more cannabinoids may be added as isolated cannabinoids, either naturally or artificially derived. Isolated cannabinoids are in powder form and requires relatively smaller emulsifying capacity when mixed into a water/ethanol solution. Cannabinoids provided as hemp oil or cannabis oil may be incorporated, but preferably with higher emulsification load. The resulting mouthwash solution using hemp oil or cannabis oil may separate.
[0066] Cannabinoids as used in this embodiment are THC, CBD, and CBG, preferably CBD and CBG. A combination of different cannabinoids may be used in this embodiment. Cannabinoids are present in this embodiment at 0.5% to 4% by weight of the mouthwash solution.
[0067] If hemp oil or cannabis oil with high cannabinoid concentration is used, the total cannabinoid content added may be present at 0.5% to 4% by weight of the mouthwash. When hemp oil or cannabis oil is used, a combination of cannabinoids may be present.
[0068] The mouthwash solution may include surfactants. Suitable nonionic surfactants may be poly-ethoxylated sorbitol esters, polycondensates of ethylene oxide and propylene oxide, poly-ethoxylated hydrogenated castor oil (available as Eumulgin HRE40, sold by BASF). Suitable anionic surfactants are sodium dodecyl sulfate (sodium laurylsulfate), sodium laureth sulfate, sodium lauroyl sarcosinate, and potassium lauryl sulfate. Suitable amphoteric surfactants include, for example, long chain imidazoline and long chain alkyl betaines. Suitable cationic surfactants include D,L-2-pyrrolidone-5-carboxylic acid salt of ethyl-N-cocoyl-L-alginate and cocamidopropyl PG dimonium chloride phosphate. Surfactants may be present in this embodiment at 0.5% to 10% (w/w), more preferably at 0.5% to 5% (w/w).
[0069] The mouthwash solution may further include thickeners. Suitable thickeners may be methylcellulose, hydroxyalkylcellulose ethers, alkylcellulose ethers, hydroxypropyl methylcellulose, gum tragancanth, sodium carboxymethylcellulose, blanose cellulose gum (available as Blanose 7LF, sold by Ashland), polyvinyl pyrrolidone (available as Plasdone C-30,
sold by Ashland), and carrageenan. Thickeners also act as emulsifiers to promote mixing in the suspension. The thickening agent may be present in the mouthwash solution at 0.5% to 5% (w/w).
[0070] The mouthwash solution preferably further comprises a humectant. Humectants retain water and prevent the solution from drying out. Suitable humectants may be chosen from a group comprising of glycerine, sorbitol, propylene glycol, and polyethylene glycol. A combination of more than one humectants may also be used. Humectants may be present in the mouthwash solution at 2% to 10% (w/w).
[0071] The mouthwash may further include cavity prevention and/or re-mineralization agents. Suitable cavity prevention or remineralization agents may be sodium monofluorophosphate and sodium fluoride. The cavity prevention agent may be present in the mouthwash solution at 0.01% to 0.5% (w/w).
[0072] The mouthwash according to this embodiment may further comprise an additional anti-bacterial agent such as lactoferrin. Lactoferrin attacks biofilm bacteria and acts as a wound- dressing agent to promote healing.
[0073] The mouthwash according to this embodiment may further comprise at least one flavor. Flavors as used this embodiment may be wintergreen, peppermint, spearmint, cinnamon, orange, watermelon, citrus, peach, apricot, anise, vanilla, clove, green tea, caraway, eucalyptus, sage thyme, bourbon, rye, or any suitable flavors. Multiple flavors may be added.
[0074] Coloring agents to give the mouthwash a desirable color may be added. Popular colors may be white, blue, orange, gold, and green. Coloring agents may be present in the mouthwash at 1% to 3% by weight.
[0075] Preservatives suitable for food products may be added into the mouthwash according to this embodiment. Suitable preservatives include citric acid, trisodium citrate, alcohols, sodium paraben, benzoates, and dichlorinated phenols. Preservatives may be present at 0.05% to 2% (w/w).
[0076] The mouthwash solution may have an aqueous base comprising water and ethanol. Ethanol increases solubility of powder cannabinoids. Ethanol may be present in this mouthwash at 5% to 20% (w/w).
[0077] The mouthwash solution may be used by a mammal, preferably a human being, by placing an appropriate amount of the mouthwash in the human subject's mouth, the human subject
holds the mouthwash in the oral cavity for at least thirty (30) seconds, and the human subject spits the mouthwash out.
[0078] Various oral infectious diseases may be treated with cannabinoid oral care solutions due to their antibacterial, pain relieving, wound dressing, and anti-inflammation properties. Conditions treated by these cannabinoid oral care compositions may include periimplantitis, periodontitis, oral mucositis (especially oral mucositis caused by chemotherapy in cancer treatment), and dental pain.
[0079] Cannabinoid dentifrice, including cannabinoid toothpaste and cannabinoid tooth powder, may be used in teeth brushing at a therapeutically effective amount to treat periimplantitis, periodontitis, oral mucositis, and dental pain.
[0080] Cannabinoid mouthwash may be used in conjunction with, or separately from, cannabinoid dentifrice. A therapeutically effective amount of cannabinoid mouthwash may be held in the oral cavity of a human subject for at least thirty seconds before spitting out for treatment of periimplantitis, periodontitis, oral mucositis, and dental pain.
EXAMPLES
Example 1
[0081] This formulation makes 3000 grams of toothpaste. All ingredients are obtained and weighed according to Table 1.
[0082] The following ingredients are obtained: Glycerin 99% Ph Eur by Sigma-Aldrich, trisodium citrate.2aq Ph Eur by Sigma-Aldrich, PEG-1500 by Sigma-Aldrich, Zeodent 113 (abrasive agent) and Zeodent 163 (thickener) by Huber Engineered Materials , Tego Betain ZF (foaming agent) by Prospector, Blanose CMC 12M31XP (binder) by Ashland.
[0083] Other ingredients are purified water, FD&C Blue No.1 (0.2% solution) for coloring, methyl salicilate (wintergreen flavor), Flavor RV35640 (peppermint flavor), sodium methylparaben (preservative), citric acid (preservative), saccharine (flavor), xylitol (cavity prevention), magnesium sulfate7.aq (anti-inflammation agent), sodium fluoride (remineralized agent), hemp oil with 3% w/w CBD and 17% w/w CBG (anti-bacterial agent, wound dressing agent), lactoferrin (anti-bacterial agent, wound dressing agent).
[0084] Table 1. Ingredients for cannabinoid toothpaste
Raw Material % (w/w) Weight (g)
Glycerine 99% Ph Eur 56.0800 1682.4000
Water 15.0000 450.0000
FD&C Blue No.l (0,2% -solution) 2.0000 60.0000
Methyl salicilate 0.2000 6.0000
Sodium methylparaben 0.1500 4.5000
Citric acid 0.0800 2.4000
Saccharine 0.2500 7.5000
Xylitol 0.2500 7.5000
Tri-Sodium Citrate.2aq Ph Eur 0.3400 10.2000
Magnesium Sulfate.7aq 0.4300 12.9000
Sodium fluoride 0.2200 6.6000
Hemp oil CBD/CBG (3%/17%) 2.0000 60.0000
Zeodent 113 8.0000 240.0000
Zeodent 163 8.0000 240.0000
Flavor RV35640 Peppermint 1.5000 45.0000
Tego Betain ZF 3.0000 90.0000
Blanose CMC12M31XP 0.5000 15.0000
PEG 1500 1.7500 52.5000
Lactofemn 0.2500 7.5000
Total 100.0000 3000.0000
[0085] Stage 1: 450 grams of water are placed in the main mixer.
[0086] Stage 2: 15 grams of Blanose CMC 12M31XP, 240 grams of Zeodent 113 and Zeodent 163 each, and 60 grams of hemp oil (CBD/CBG 3%/17% w/w) ) are dry mixed in a different vessel, then added into the main mixer. The main mixer mixes for 10 minutes and produces a cream-like paste.
[0087] Stage 3: In a different vessel, mix 1200 grams of the glycerin solution, saccharine, sodium fluoride, sodium methylparaben, xylitol, citric acid, trisodium citrate.2aq Ph Eur, magnesium sulfate. 7aq, PEG 1500, and lactoferrin. The vessel is heated to increase dissolution. This mixture is added into the main mixer and mixed for 15 minutes.
[0088] Stage 4: A mixture of Tego Betain ZF and the rest of the glycerin solution is added into the main mixer and mixed for 15 minutes.
[0089] Stage 5: Methyl salicilate and peppermint flavor are added into the main mixer and mixed for another 10 minutes. The toothpaste is then packed into tubes or pump containers.
Example 2
[0090] This formulation makes 100 grams of tooth powder.
[00911 Table 2. Ingredients for cannabinoid tooth powder
Raw Material % (w/w) Weight (g)
Baking soda 39.7000 39.7000
Clay 30.0000 30.0000
Cannabidiol (powder) 0.1000 0.1000
Cannabigerol (powder) 0.2000 0.2000
Xylitol 20.0000 20.0000
Peppermint oil 10.0000 10.0000
Total 100.0000 100.0000
[0092] Weigh and combine baking soda, clay, cannabidiol, and xylitol according to the weight percentage given above. Mix well in a solid mixer; then add 10 grams of peppermint oil and mix for another 5 minutes. The resulting tooth powder is packaged into jars.
Example 3
[0093] This formulation makes lOOOg of mouthwash
[0094] Table 3. Ingredient for cannabinoid mouthwash
Raw material % (w/w) Weight (g)
Water 81.010 810.100
Ethanol 10.000 100.000
Glycerine 99% Ph Eur 3.000 30.000
Blanose 7LF 0.300 3.000
Tri-Sodium Citrate.2aq Ph Eur 0.340 3.400
Sodium methylparaben 0.150 1.500
Xylitol 0.100 1.000
Magnesium Sulfate.7aq 0.050 0.500
Plasdone C-30 1.000 10.000
CBD/CBG (3%/17%) 0.060 0.600
CBG 0.340 3.400
Lactoferrine 0.200 2.000
Sodium laurylsulfate 1.000 10.000
Eumulgin HRE40 1.500 ! 15.000 1
Sodium fluoride 0.050 j 0.500 j
Methyl salicilate o.ioo ; 1.000 i
Flavor RV35641 Peppermint 0.300 ! 3.000 I
Citric acid 0.500 j 5.000 j
Total 100.0000 ! 1000.0000
[0095] All ingredients are obtained according to the list above. Mix all ingredients except for water and ethanol in a stainless steel container while mixing with a propeller. Add ethanol while continue to mix, then add water. The mixture is mixed for another 30 minutes. This formula makes lOOOg of mouthwash.
[0096] Variations and modifications will occur to those of skill in the art after reviewing this disclosure. The disclosed features may be implemented, in any combination and subcombination (including multiple dependent combinations and sub-combinations), with one or more other features described herein. The various features described or illustrated above, including any components thereof, may be combined or integrated in other systems. Moreover, certain features may be omitted or not implements.
[0097] Examples of changes, substitutions, and alterations are ascertainable by one skilled in the art and could be made without departing from the scope of the information disclosed herein. All references cited are hereby incorporated by reference herein in their entireties and made part of this application.
Claims
1. A cannabinoid toothpaste composition comprising:
(a) at least one abrasive agent selected from the group consisting of abrasive silica, hydrated alumina, water-insoluble sodium metaphosphate, tricalcium phosphate, calcium phosphate dihydrate, anhydrous dicalcium phosphate, calcium pyrophosphate, calcium carbonate, sodium bicarbonate, and aluminum silicate;
(b) at least one binder selected from the group consisting of guar gum, xanthan gum, sodium alginate, karaya gum, bentonite, carrageenan, and methylcellulose;
(c) a humectant selected from the group consisting of sorbitol solution and glycerin solution;
(d) a fluoridating agent selected from the group consisting of sodium fluoride, potassium fluoride, calcium fluoride, sodium fluorosilicate, acidulated phosphate fluoride, difluorosilane, sodium monofluorophosphate, ammonium fluorosilicate, and stannous fluoride;
(e) a surfactant selected from the group consisting of sodium lauryl sulfate, sodium lauryl sulfoacetate, dioctyl sodium sulfosuccinate, sulfolaurate, sodium lauryl sarcosinate, sodium stearyl fumarate, and sodium stearyl lactate;
(f) water;
(g) a thickener; and
(h) one or more cannabinoids selected from the group consisting of Δ9- tetrahydrocannabinols, cannabidiol, and cannabigerol.
2. The cannabinoid toothpaste of Claim 1, wherein the one or more cannabinoids is present in an amount of 0.1 to 0.5 weight percent.
3. The cannabinoid toothpaste of Claim 1, further comprising one or more anti- inflammation agents.
4. The cannabinoid toothpaste of Claim 3, wherein the anti-inflammation agent is lactoferrin.
5. The cannabinoid toothpaste of Claim 4, further comprising one or more coloring agents.
6. The cannabinoid toothpaste of Claim 5, further comprising one or more sweeteners chosen from a group comprising of saccharin, aspartame, and diglyzzherizins.
7. The cannabinoid toothpaste of Claim 6, further comprising one or more preservatives chosen from a group comprising of citric acid, trisodium citrate, alcohols, benzoates, and dichlorinated phenols.
8. The cannabinoid toothpaste of Claim 7, further comprising at least one flavor selected from the group consisting of spearmint, peppermint, wintergreen, cinnamon, orange, watermelon, citrus, peach, apricot, anise, vanilla, clove, green tea, caraway, eucalyptus, sage, thyme, bourbon, and rye.
9. A cannabinoid tooth powder composition comprising:
(a) at least one abrasive agent selected from the group consisting of baking soda, chalk, clay, activated carbon, or pumice powder;
(b) a sweetener; and
(c) one or more cannabinoids in powder form.
10. The cannabinoid tooth powder of Claim 9, wherein the one or more cannabinoids is present at between about 0.05 to 0.3 weight percent.
11. The cannabinoid tooth powder of Claim 10, further comprising a flavor selected from the group consisting of peppermint, spearmint, wintergreen, cinnamon, orange, watermelon, citrus, peach, apricot, anise, vanilla, clove, green tea, caraway, eucalyptus, sage, thyme, bourbon, and rye.
12. A cannabinoid mouthwash composition comprising:
(a) at least one cannabinoid;
(b) a surfactant selected from the group consisting of poly-ethoxylated sorbitol esters, polycondensates of ethylene oxide, propylene oxide, poly-ethoxylated hydrogenated castor oil, sodium dodecyl sulfate, sodium laureth sulfate, sodium lauroyl sarcosinate, and potassium lauryl sulfate, long chain imidazoline and long chain alkyl betaines, D,L-2-pyrrolidone-5-carboxylic acid salt of ethyl-N-cocoyl-L-alginate, and cocamidopropyl PG dimonium chloride phosphate;
(c) a thickener selected from the group consisting of methylcellulose, hydroxyalkylcellulose ethers, alkylcellulose ethers, hydroxypropyl methylcellulose, gum tragancanth, sodium carboxymethylcellulose, blanose cellulose gum, polyvinyl pyrrolidone, and carrageenan;
(d) a humectant selected from the group consisting of glycerine, sorbitol, propylene glycol, and polyethylene glycol;
(e) a preservative selected from the group consisting of citric acid, trisodium citrate, alcohols, sodium paraben, benzoates, and dichlorinated phenols;
(f) ethanol; and
(g) water.
13. The cannabinoid mouthwash composition of Claim 12, wherein:
the at least one cannabinoid is present at 0.5 to 4 weight percent;
the surfactant is present at 0.5 to 10 weight percent;
the thickener is present at 0.5 to 5 weight percent; and
the humectant is present at 2 to 10 weight percent.
14. The cannabinoid mouthwash composition of Claim 13, further comprising a cavity prevention agent selected from the group consisting of sodium monofluorophosphate and sodium chloride.
15. The cannabinoid mouthwash composition of Claim 14, further comprising an antibacterial agent.
16. The cannabinoid mouthwash composition of Claim 15, further comprising at least one flavor selected from the group consisting of wintergreen, peppermint, spearmint, cinnamon, orange, watermelon, citrus, peach, apricot, anise, vanilla, clove, green tea, caraway, eucalyptus, sage, thyme, bourbon, and rye.
17. The cannabinoid mouthwash composition of Claim 16, further comprising a food coloring agent.
18. Use of cannabinoids for the manufacture of a cannabinoid dentifrice for the treatment of an oral infectious condition.
19. The use of cannabinoids according to Claim 18, wherein the oral infectious condition is selected from the group consisting of periimplantitis, periodontitis, oral mucositis, and dental pain.
20. Use of cannabinoids for the manufacture of a cannabinoid mouthwash for the treatment of an oral infectious condition.
21. The use of cannabinoids according to Claim 20, wherein the oral infectious condition is selected from the group consisting of periimplantitis, periodontitis, oral mucositis, and dental pain.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21165551.9A EP3865113A1 (en) | 2014-12-16 | 2015-12-16 | Oral care composition comprising cannabinoids |
EP15870986.5A EP3233021A4 (en) | 2014-12-16 | 2015-12-16 | Oral care composition comprising cannabinoids |
HK18103553.3A HK1243949A1 (en) | 2014-12-16 | 2018-03-14 | Oral care composition comprising cannabinoids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462092609P | 2014-12-16 | 2014-12-16 | |
US62/092,609 | 2014-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016100516A1 true WO2016100516A1 (en) | 2016-06-23 |
Family
ID=56110093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/066099 WO2016100516A1 (en) | 2014-12-16 | 2015-12-16 | Oral care composition comprising cannabinoids |
Country Status (5)
Country | Link |
---|---|
US (3) | US10172786B2 (en) |
EP (2) | EP3233021A4 (en) |
HK (1) | HK1243949A1 (en) |
MA (1) | MA41212A (en) |
WO (1) | WO2016100516A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106236638A (en) * | 2016-08-24 | 2016-12-21 | 皖南医学院 | A kind of gel dentifrice with antiinflammatory sterilization teeth consolidating effect and preparation method thereof |
US20190076343A1 (en) * | 2017-09-14 | 2019-03-14 | Gerald P. Curatola | Oral care formulations and methods for use |
EP3576731A4 (en) * | 2017-02-02 | 2020-01-15 | Panaxia Pharmaceutical Industries Ltd. | Composition for buccal or sublingual administration of cannabis extract and methods for making same |
GB2586841A (en) * | 2019-09-05 | 2021-03-10 | Malhotra Rohan | A lubricating strip for a shaving device, and method of use thereof |
WO2021084543A1 (en) * | 2019-10-31 | 2021-05-06 | M. Mustix Ltd | Treatment of tooth decay using a chewing gum composition comprising cannabinoids |
US11007170B2 (en) | 2017-02-02 | 2021-05-18 | Panaxia Pharmaceutical Industries Ltd. | Composition for buccal or sublingual administration of cannabis extract and methods for making same |
WO2021124316A1 (en) * | 2019-12-17 | 2021-06-24 | Swysh Inc. | High cbd cannabis sativa lines and extracts with anti-inflammatory potencies for oral and gut health |
CN113116870A (en) * | 2019-12-31 | 2021-07-16 | 四川大学 | Application of cannabidiol in preparation of medicine for promoting oral mucosa healing |
CN113398049A (en) * | 2021-07-16 | 2021-09-17 | 深圳市西马龙科技有限公司 | Toothpaste containing antibacterial and anti-inflammatory components and preparation method thereof |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
US10172786B2 (en) | 2014-12-16 | 2019-01-08 | Axim Biotechnologies, Inc. | Oral care composition comprising cannabinoids |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
US10542770B2 (en) | 2016-03-18 | 2020-01-28 | Aceso Wellness LLC | Cannabinoid emulsion product and process for making the same |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
US10933013B1 (en) * | 2016-04-25 | 2021-03-02 | Ethan D Dean | Oral hygiene compositions containing extract of cannabis plant |
GB2551985B (en) * | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
CN109789095A (en) | 2016-07-25 | 2019-05-21 | Ebbu 公司 | New hemp tablet formulation and composition and its manufacturing method |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
CA3044403A1 (en) * | 2016-12-21 | 2018-06-28 | Colgate-Palmolive Company | Oral care compositions and methods of use |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
US12030908B2 (en) | 2017-03-10 | 2024-07-09 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
US11377468B2 (en) | 2017-03-10 | 2022-07-05 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
US11795192B2 (en) | 2017-03-10 | 2023-10-24 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
US20180333349A1 (en) * | 2017-05-17 | 2018-11-22 | Colgate-Palmolive Company | Oral Care Compositions and Methods of Use |
EP3664795B1 (en) | 2017-08-09 | 2024-06-19 | Cannibite BVBA | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects |
CN111356409A (en) * | 2017-10-04 | 2020-06-30 | 坎尼拜特有限责任公司 | System and method for detecting intraoral disease and determining personalized treatment regimens |
CN109939012A (en) * | 2017-12-20 | 2019-06-28 | 汉义生物科技(北京)有限公司 | Application of the cannabidiol in tooth whitening |
CN109939014A (en) * | 2017-12-20 | 2019-06-28 | 汉义生物科技(北京)有限公司 | A kind of flavorants containing cannboid |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
EP3793542A4 (en) * | 2018-05-14 | 2022-03-30 | Buzzelet Development And Technologies Ltd | Terpene-enriched cannabinoid compositions and uses thereof in the treatment of infectious conditions |
EP3806686A4 (en) * | 2018-06-12 | 2022-03-23 | Buzzelet Development And Technologies Ltd | Dental care cannabis device and use thereof |
US11185526B2 (en) | 2018-09-04 | 2021-11-30 | Babak Ghalili | Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods |
US11147775B2 (en) | 2018-09-04 | 2021-10-19 | Babak Ghalili | Cannabinoid and menthol gel compositions, patches and methods |
US10751299B2 (en) | 2018-09-04 | 2020-08-25 | Babak Ghalili | Cannabinoid and menthol compositions and methods |
US10966924B2 (en) | 2018-09-04 | 2021-04-06 | Babak Ghalili | Veterinary cannabinoid, menthol and anesthetic compositions and methods |
EP3866810A4 (en) * | 2018-10-17 | 2022-07-27 | Lakewood Amedex, Inc. | Methods and compositions for treating oral mucositis |
US11026881B2 (en) * | 2019-01-02 | 2021-06-08 | Daniel S. Nam | Sedative laced toothpaste |
CA3136620C (en) * | 2019-04-10 | 2023-12-05 | Black Tulip Management, Inc. | Oral rinse compositions for reducing pathogens underlying tooth decay, periodontitis and oral malodor |
EP3952827A4 (en) * | 2019-04-10 | 2023-06-07 | Black Tulip Management, Inc. | Oral rinse compositions for reducing pathogens underlying and for treating periodontal disease and oral malodor in the canine |
IT201900006427A1 (en) * | 2019-04-29 | 2020-10-29 | Maria Teresa Marinelli | Anhydrous preparation for powdered toothpaste |
US20200352206A1 (en) * | 2019-05-08 | 2020-11-12 | Christine Wagner-Salvini | Composition and method for mushroom mycelial compound and botanical mixture |
IL267081A (en) * | 2019-06-04 | 2019-08-29 | Cannibite Bvba | Compositions methods and device for enhancing dental care |
MX2022003868A (en) * | 2019-10-07 | 2022-04-18 | Colgate Palmolive Co | Oral care composition comprising a cannabinoid. |
US20240091110A1 (en) * | 2019-10-07 | 2024-03-21 | Colgate-Palmolive Company | Oral Care Compositions and Methods of Use |
US20220304917A1 (en) * | 2019-10-07 | 2022-09-29 | Colgate-Palmolive Company | Personal Care Compositions and Methods |
AU2020405221B2 (en) | 2019-12-16 | 2023-11-09 | Colgate-Palmolive Company | Personal care compositions and methods for the same |
US11273122B2 (en) * | 2020-02-11 | 2022-03-15 | Therese Mainella | Combination of cannabis, derivatives thereof and additives in oral care compositions |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
WO2021178465A1 (en) * | 2020-03-02 | 2021-09-10 | Clear Lake Research, Llc | Buccal and enteric delivery of fatty acids with oral hygiene practices |
CA3183864A1 (en) * | 2020-06-22 | 2021-12-30 | Glynn Wilson | Oronasal cbd formulations and uses thereof |
CN111671698A (en) * | 2020-08-05 | 2020-09-18 | 江西草珊瑚口腔护理用品有限公司 | Cannabinoid-containing functional toothpaste |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US20220125696A1 (en) * | 2020-10-25 | 2022-04-28 | John Christian Haught | Inflammation reducing composition containing a cannabis sativa compound |
CN112791029A (en) * | 2021-03-12 | 2021-05-14 | 云南根之然生物科技有限公司 | Composition containing industrial hemp root microcapsule and plant extract and application thereof |
WO2022204731A1 (en) * | 2021-03-26 | 2022-09-29 | Demetrix, Inc. | Oral care product with cannabinoid compounds |
WO2022232825A1 (en) * | 2021-04-28 | 2022-11-03 | Demetrix, Inc. | Use of cannabinoids in the treatment of oral inflammation and periodontal disease |
CN113384487A (en) * | 2021-06-30 | 2021-09-14 | 广州名大实业有限公司 | Formula of toothpaste capable of efficiently removing smoke spots |
US20230037975A1 (en) * | 2021-07-30 | 2023-02-09 | Demetrix, Inc. | Use of cannabinoid compounds in oral care compositions to inhibit the growth of p. gingivalis |
CZ309967B6 (en) * | 2021-08-07 | 2024-03-13 | Cb21 Pharma, S.R.O. | Medicinal product in the form of dental gel |
CN114533782A (en) * | 2021-12-20 | 2022-05-27 | 汉木森新药研发(深圳)有限公司 | Application of full-spectrum CBD oil in preparation of medicine for preventing or treating periodontitis |
EP4382102A1 (en) | 2022-12-08 | 2024-06-12 | UAB Fitodenta | Compositions for use in post-operative pain and inflammation treatment |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4547362A (en) * | 1983-03-14 | 1985-10-15 | Church & Dwight Co., Inc. | Sodium-bicarbonate-containing tooth powder |
US5330749A (en) * | 1993-06-10 | 1994-07-19 | Church & Dwight Co., Inc. | Liquid mouthwash containing a particulate bicarbonate suspension |
US20080112901A1 (en) * | 2004-07-02 | 2008-05-15 | Discus Dental, Llc | Dental Compositions with Sensitivity Relief |
US20120021075A1 (en) * | 2010-07-26 | 2012-01-26 | Ida Umanskaya | Dual-chamber packaging systems for cannabis-infused products systems |
US20120214766A1 (en) | 2009-08-28 | 2012-08-23 | Jones Robert M | Cannabinoid receptor modulators |
KR20120133135A (en) | 2011-05-30 | 2012-12-10 | 한국 한의학 연구원 | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Cannabis sativa |
US20130230469A1 (en) * | 2010-11-12 | 2013-09-05 | Colgate-Palmolive Company | Oral Care Product and Methods of Use and Manufacture Thereof |
CN103784336A (en) * | 2014-01-26 | 2014-05-14 | 泰州比尔夫生物科技有限公司 | Toothpaste containing bovine lactoferrin |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1817664A (en) * | 1928-10-26 | 1931-08-04 | Bernard B Badanes | Dentifrice |
GB8719775D0 (en) * | 1987-08-21 | 1987-09-30 | Unilever Plc | Oral products |
US5898037A (en) * | 1992-11-13 | 1999-04-27 | Marx; Alvin J. | Formulations of magnesium compounds for local application and methods of treatment using the same |
GB9807639D0 (en) * | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
DE19834355A1 (en) * | 1998-07-30 | 2000-02-03 | Henkel Kgaa | Anti-inflammatory dentifrices |
GB2394894B (en) * | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
EP1720411A1 (en) * | 2004-02-24 | 2006-11-15 | Campina B.V. | Antimicrobial lactoferrin compositions for surfaces, cavities, and foodstuff |
US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
ITMI20052351A1 (en) * | 2005-12-09 | 2007-06-10 | Microbo Srl | NEW PHARMACEUTICAL USE OF TRANSFERRIN AND DERIVED PHARMACEUTICAL COMPOSITIONS |
CA2698752A1 (en) * | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Oral cannabinoid liquid formulations and methods of treatment |
US8113729B2 (en) * | 2009-07-08 | 2012-02-14 | Dental Development Systems, Llc | Toothpaste droplets |
US9818073B2 (en) | 2009-07-17 | 2017-11-14 | Honeywell International Inc. | Demand response management system |
IN2012DN01100A (en) * | 2009-08-07 | 2015-04-10 | Fmc Corp | |
US20130197710A1 (en) | 2010-04-26 | 2013-08-01 | Dong Energy A/S | Dispatch controller for a distributed electrical power system |
TWI423022B (en) * | 2011-02-15 | 2014-01-11 | Phison Electronics Corp | Memory management method, memory controller and memory storage apparatus |
US9088179B2 (en) | 2011-08-22 | 2015-07-21 | Cisco Technology, Inc. | Adaptive control of power grid operations based on energy profiles |
CN102895147B (en) * | 2012-09-25 | 2015-04-29 | 广州中汉口腔用品有限公司 | Toothpaste with anti-inflammation and anti-allergic effects and making technology thereof |
GB2506401A (en) | 2012-09-28 | 2014-04-02 | Ibm | Method for allocating electrical energy in a smart grid |
US20140166028A1 (en) * | 2012-12-14 | 2014-06-19 | Richard C. Fuisz | Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor or Smoke Producing Device Through Use of an Absorption Conditioning Unit |
US9312698B2 (en) | 2012-12-19 | 2016-04-12 | Robert Bosch Gmbh | System and method for energy distribution |
WO2015054869A1 (en) | 2013-10-17 | 2015-04-23 | 国网新源张家口风光储示范电站有限公司 | Megawatt-level battery energy storage power station monitoring system and method therefor |
KR101553451B1 (en) | 2013-12-30 | 2015-09-16 | 주식회사 효성 | Method and apparatus for distributing electric power on energy storage system |
JP2016039728A (en) | 2014-08-08 | 2016-03-22 | 株式会社デンソー | Controller for storage battery system |
US10172786B2 (en) | 2014-12-16 | 2019-01-08 | Axim Biotechnologies, Inc. | Oral care composition comprising cannabinoids |
NO20150349A1 (en) | 2015-03-20 | 2016-08-22 | Kongsberg Maritime As | Dynamic hybrid control |
US10270275B2 (en) | 2015-08-27 | 2019-04-23 | General Electric Company | Systems and methods for controlling energy storage systems having multiple battery types |
DE102017202136A1 (en) | 2017-02-10 | 2018-08-16 | Siemens Aktiengesellschaft | Energy storage device and its use |
-
2015
- 2015-12-15 US US14/970,322 patent/US10172786B2/en active Active
- 2015-12-16 EP EP15870986.5A patent/EP3233021A4/en not_active Withdrawn
- 2015-12-16 EP EP21165551.9A patent/EP3865113A1/en active Pending
- 2015-12-16 WO PCT/US2015/066099 patent/WO2016100516A1/en active Application Filing
- 2015-12-16 MA MA041212A patent/MA41212A/en unknown
-
2018
- 2018-03-14 HK HK18103553.3A patent/HK1243949A1/en unknown
- 2018-11-08 US US16/184,747 patent/US20190076349A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/920,065 patent/US11890361B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4547362A (en) * | 1983-03-14 | 1985-10-15 | Church & Dwight Co., Inc. | Sodium-bicarbonate-containing tooth powder |
US5330749A (en) * | 1993-06-10 | 1994-07-19 | Church & Dwight Co., Inc. | Liquid mouthwash containing a particulate bicarbonate suspension |
US20080112901A1 (en) * | 2004-07-02 | 2008-05-15 | Discus Dental, Llc | Dental Compositions with Sensitivity Relief |
US20120214766A1 (en) | 2009-08-28 | 2012-08-23 | Jones Robert M | Cannabinoid receptor modulators |
US20120021075A1 (en) * | 2010-07-26 | 2012-01-26 | Ida Umanskaya | Dual-chamber packaging systems for cannabis-infused products systems |
US20130230469A1 (en) * | 2010-11-12 | 2013-09-05 | Colgate-Palmolive Company | Oral Care Product and Methods of Use and Manufacture Thereof |
KR20120133135A (en) | 2011-05-30 | 2012-12-10 | 한국 한의학 연구원 | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Cannabis sativa |
CN103784336A (en) * | 2014-01-26 | 2014-05-14 | 泰州比尔夫生物科技有限公司 | Toothpaste containing bovine lactoferrin |
Non-Patent Citations (4)
Title |
---|
"DATABASE", Database accession no. 2636061 |
KHAN ET AL.: "Antibacterial properties of Hemp and other natural fibre plants: A review.", BIORESOURCES |
KHAN ET AL.: "Antibacterial properties of Hemp and other natural fibre plants: A review.", BIORESOURCES, vol. 9, no. 2, 4 February 2014 (2014-02-04), pages 3642 - 3659, XP055457085 * |
See also references of EP3233021A4 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106236638A (en) * | 2016-08-24 | 2016-12-21 | 皖南医学院 | A kind of gel dentifrice with antiinflammatory sterilization teeth consolidating effect and preparation method thereof |
CN106236638B (en) * | 2016-08-24 | 2020-06-12 | 皖南医学院 | Gel toothpaste with anti-inflammatory, antibacterial and teeth strengthening effects and preparation method thereof |
EP3576731A4 (en) * | 2017-02-02 | 2020-01-15 | Panaxia Pharmaceutical Industries Ltd. | Composition for buccal or sublingual administration of cannabis extract and methods for making same |
US11007170B2 (en) | 2017-02-02 | 2021-05-18 | Panaxia Pharmaceutical Industries Ltd. | Composition for buccal or sublingual administration of cannabis extract and methods for making same |
US11590100B2 (en) | 2017-02-02 | 2023-02-28 | Panaxia Pharmaceutical Industries Ltd. | Composition for buccal or sublingual administration of cannabis extract and methods for making same |
IL268352B2 (en) * | 2017-02-02 | 2023-06-01 | Panaxia Pharmaceutical Ind Ltd | Composition for buccal or sublingual administration of cannabis extract and methods for making same |
US20190076343A1 (en) * | 2017-09-14 | 2019-03-14 | Gerald P. Curatola | Oral care formulations and methods for use |
GB2586841A (en) * | 2019-09-05 | 2021-03-10 | Malhotra Rohan | A lubricating strip for a shaving device, and method of use thereof |
WO2021084543A1 (en) * | 2019-10-31 | 2021-05-06 | M. Mustix Ltd | Treatment of tooth decay using a chewing gum composition comprising cannabinoids |
WO2021124316A1 (en) * | 2019-12-17 | 2021-06-24 | Swysh Inc. | High cbd cannabis sativa lines and extracts with anti-inflammatory potencies for oral and gut health |
CN113116870A (en) * | 2019-12-31 | 2021-07-16 | 四川大学 | Application of cannabidiol in preparation of medicine for promoting oral mucosa healing |
CN113398049A (en) * | 2021-07-16 | 2021-09-17 | 深圳市西马龙科技有限公司 | Toothpaste containing antibacterial and anti-inflammatory components and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
MA41212A (en) | 2021-05-26 |
EP3865113A1 (en) | 2021-08-18 |
US10172786B2 (en) | 2019-01-08 |
US20200330339A1 (en) | 2020-10-22 |
EP3233021A4 (en) | 2018-08-15 |
US20190076349A1 (en) | 2019-03-14 |
EP3233021A1 (en) | 2017-10-25 |
HK1243949A1 (en) | 2018-07-27 |
US11890361B2 (en) | 2024-02-06 |
US20160166498A1 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11890361B2 (en) | Oral care composition comprising cannabinoids | |
KR101763953B1 (en) | Composition for oral cavity | |
AU2005316974B2 (en) | Tartar control oral care composition containing extract of magnolia | |
JP5381685B2 (en) | Dentifrice composition | |
CA2906184A1 (en) | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products | |
US11986551B2 (en) | Sedative laced toothpaste | |
KR20120086685A (en) | Dentifrice composition | |
EP2720669B1 (en) | An oral care composition | |
KR102638091B1 (en) | Toothpaste composition with whitening function | |
JP2020011951A (en) | Oral composition | |
JP4147412B2 (en) | Oral composition | |
KR20110067358A (en) | Calendula officinalis dentifrice composition and process for preparing the same | |
KR100760970B1 (en) | Tooth paste containing essential oil | |
JP6911845B2 (en) | Oral composition | |
US11273122B2 (en) | Combination of cannabis, derivatives thereof and additives in oral care compositions | |
JP4158036B2 (en) | Dentifrice composition and method for producing the same | |
JP6753142B2 (en) | Oral composition | |
RU2777153C1 (en) | Composition for oral care for patients with metabolic disorders | |
JP2004182649A (en) | Composition for oral cavity | |
JP7087782B2 (en) | Oral composition | |
WO2022138487A1 (en) | Oral composition | |
RO135708A2 (en) | Process for preparing a mouthwash for pregnancy gingivitis | |
JP2021143151A (en) | Oral composition | |
WO2015137302A1 (en) | Oral cavity composition and gloss-imparting agent for tooth surfaces | |
JP2002284691A (en) | Composition for oral cavity taken before meal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15870986 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015870986 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |